Deletion 9q34.3 syndrome: genotype-phenotype correlations and an extended deletion in a patient with features of Opitz C trigonocephaly

S A Yatsenko, S W Cheung, D A Scott, M J M Nowaczyk, M Tarnopolsky, S Naidu, G Bibat, A Patel, J G Leroy, F Scaglia, P Stankiewicz, J R Lupski

J Med Genet 2005;42:328–335. doi: 10.1136/jmg.2004.028258

Submicroscopic deletion del(9)(q34.3) is a rare constitutional microdeletion syndrome involving the gene-rich subtelomeric region of the long arm of chromosome 9, with about 30 cases reported.^{1–12} Visible constitutional 9q34 deletions are extremely rare, with only a few cases described.^{2 10 12} The low prevalence of large terminal deletions at the 9q34 chromosome region in liveborns is thought to reflect lethality in early embryogenesis.¹³

At least 18 patients with 9q34.3 microdeletions detected by fluorescence in situ hybridisation (FISH) testing, in whom normal karyotypes were initially obtained, have been reported.^{1 5–7 11} Many patients carry a cryptic del(9)(q34.3) that may result in a clinically recognisable phenotype characterised by severe developmental delay, mental retardation, hypotonia, congenital heart defects (CHD), seizures, and prominent craniofacial features including microcephaly, arched eyebrows, hypertelorism, short nose with anteverted nostrils, open mouth, and a protruding tongue.^{6 7 11} Recently, based on clinical and molecular breakpoint analyses using FISH, microsatellites, and single nucleotide polymorphism (SNP) genotyping, two research groups have independently identified an ~1.0 Mb shortest region of overlap (SRO) of 9q34.3 deletions.^{6 11} Although the clinical criteria and incidence of the 9q34.3 deletion are not yet well established, the increasing number of patients reported with del(9)(q34.3) is probably related to the widespread clinical application of telomere FISH. Hence, this microdeletion syndrome may be more common than previously thought.

We have identified a 9q34.3 deletion in each of five unrelated patients, including a patient with clinical features similar to Opitz trigonocephaly C syndrome (OTCS; MIM211750). A monogenic cause and autosomal recessive mode of inheritance have been considered probable in OTCS, usually associated with a normal karyotype.^{14–19} In contrast, several reports on patients with multiple congenital anomalies resembling OTCS and chromosomal imbalance of either 3p, 3q, 9p, or 11q, supported the hypothesis that OTCS is a heterogeneous condition and may be an example of an underascertained microdeletion syndrome.^{16 18–20}

METHODS

Patients

This study was approved by the Institutional Review Board for human subjects research at Baylor College of Medicine and Affiliated Hospitals, and appropriate informed consents for children were obtained from their parents. The present research includes five unrelated children (two boys and three girls) aged from 1 to 9 years. Patients KCL1, KCL2, KCL3, KCL4, and KCL5 had an initial clinical evaluation for congenital anomalies, facial dysmorphism, hypotonia, postnatal microcephaly, unexplained mental retardation, and speech delay. They were referred for cytogenetic and

Key points

- Approximately 30 individuals with 9q34.3 deletions in association with multiple congenital anomalies, recognisable facial dysmorphism, microcephaly, mental retardation, speech delay, seizures, and hypotonia, have been described recently. We report on five unrelated patients with de novo terminal 9q34.3 microdeletions, including one patient with some clinical features resembling Opitz trigonocephaly C syndrome (OTCS).
- The deletion breakpoints were mapped using fluorescence in situ hybridisation analysis with BAC (bacterial artificial chromosome) and fosmid clones. The deletions varied in size from ~700 kb to 2.3 Mb. The 700 kb smallest region of overlap contains two genes, *EHMT1* and *CACNA1B*, potentially associated with the phenotypic features in 9q34.3 monosomy.
- Specific clinical endophenotypes are correlated with the extent of the deletion, and potential candidate genes discussed. The patient with OTCS-like features has the largest deletion and the most severe phenotype among these five patients with 9q34.3 deletions.
- Our results suggest that OTCS may be a complex phenotype due to haploinsufficiency of one or more genes within the 9q34.3 region. We propose that the 9q34.3 microdeletion represents a contiguous gene syndrome resulting in a complex phenotype depending on the extent of the deletion.

subtelomere testing. The two boys were Hispanic and the three girls were of northern European descent. All subjects were born to healthy, non-consanguineous parents with no known family history of mental retardation, congenital malformation, or metabolic disorders. The clinical features are summarised in table 1 and compared with those observed in patients with a pure 9q terminal deletion as well as with the anomalies documented in reported OTCS patients.

Patients KCL3, KCL4, and KCL5 had additional genetic testing for Prader-Willi, fragile X, and Rett syndromes,

Abbreviations: ASD, atrial septal defect; BAC, bacterial artificial chromosome; CHD, congenital heart defects; FISH, fluorescence in situ hybridisation; GU, genito-urinary; IHH, idiopathic hypogonadotropic hypogonadism; LCR, low copy repeat; NVDCCs, N-type voltage dependent Ca²⁺ channels; OTCS, Opitz trigonocephaly C syndrome; SNP, single nucleotide polymorphism; SRO, shortest region of overlap; VSD, ventricular septal defect

Table 1 Comparison of clinical findings observed in patients with 9q34.3 monosomy or OTCS

Manifestations	OTCS*	KCL1	KCL2	KCL3	KCL4	KCL5	This study	del 9q34.3†
9q34.3 deletion size (Mb)		2.300	1.550	1.050	0.700	0.700		
Gender	14M/14F	M	F	F	F	M	2M/3F	11M/9F
Age (years)		1 ⁴ / ₁₂	3	3 ⁹ / ₁₂	9	4 ⁸ / ₁₂		
Gestational age (weeks)		40	32	40	41	42		
FOC at birth/present (centile)		<5th/<<5th	/<<2th	25th/<2th	/10th	10th/15th		
Birth length/present height (centile)		<5th/<5th		50th/25th	/75th	25th/80th		
Weight at birth/present (centile)		<5th/<5th	5th/	50th/95th	90th/97th	25th/97th		
Survival at age 2 years	22/27 (81%)	—	+	+	+	+	4/5	17/20 (85%)
Obesity	—	—	—	—	+	+	2/5	5/19 (26%)
Microcephaly	19/26 (73%)	+	+	+	+	+	5/5	17/20 (85%)
Trigonocephaly	28/28 (100%)	+	—	—	—	—	1/5	0/20 (0%)
Prominent forehead	—	—	—	—	—	—	0/5	11/20 (55%)
Ear abnormalities	26/26 (100%)	+	+	—	+	+	4/5	9/20 (45%)
Upslanted palpebral fissures	26/27 (96%)	+	—	—	—	—	1/5	3/16 (19%)
Epicanthal folds	25/28 (89%)	—	+	—	—	—	1/5	5/17 (29%)
Synophrys, arched eyebrows	—	+	+	—	+	+	4/5	13/19 (68%)
Hypertelorism	—	+	+	+	+	+	5/5	8/19 (42%)
Broad depressed nasal bridge	21/27 (78%)	+	+	+	+	+	5/5	15/20 (75%)
Small nose with anteverted nostrils	25/28 (89%)	+	+	—	+	+	4/5	14/19 (74%)
Midfacial hypoplasia	—	+	+	—	+	+	4/5	13/20 (65%)
Micrognathia	18/27 (67%)	—	—	—	—	—	0/5	3/4 (75%)
High-arched palate	21/26 (81%)	+	+	—	—	—	2/5	4/15 (27%)
Deep furrow palate	21/26 (81%)	+	—	—	—	—	1/5	
Open “carp-like” mouth	—	+	+	—	+	—	3/5	6/8 (75%)
Large, protruding tongue	—	+	+	+	—	—	3/5	11/20 (55%)
Widely spaced teeth	—	+	+	+	+	+	5/5	
Short neck	18/25 (72%)	+	+	—	—	—	2/5	6/18 (33%)
Loose redundant skin	16/22 (73%)	—	—	—	—	—	0/5	4/15 (27%)
Haemangioma	9/19 (47%)	+	—	+	+	—	3/5	1/1
Upper limb anomalies	22/25 (88%)	+	—	—	—	—	1/5	3/17 (18%)
Single transverse palmar crease	10/24 (42%)	+	—	—	—	—	1/5	4/17 (24%)
Lower limb anomalies	17/24 (71%)	+	—	+	—	—	2/5	6/20 (30%)
Joint laxity	—	+	—	+	+	—	2/4	5/15 (33%)
Cardiac defects	16/27 (59%)	+(ASD, VSD)	+(ASD)	—	—	—	2/5	10/20 (50%)
Feeding difficulties‡	16/22 (70%)	+	+	+	+	+	5/5	3/4 (75%)
GU abnormalities	9/10 (90%)	+(Hs, Mp, Cr, KA)	—	—	—	+(SS)	2/5	8/20 (40%)
Abnormal brain MRI	5/10 (50%)	+	+	—	—	—	2/5	4/16 (25%)
Hearing loss	3/28 (11%)	—	—	—	—	—	0/5	3/19 (16%)
Hypotonia	17/24 (71%)	+	+	+	+	+	5/5	17/20 (85%)
Mental retardation/speech delay	23/24 (96%)	+	+	+	+	+	5/5	17/18 (94%)
Seizures	8/23 (35%)	+	+	—	—	—	2/5	7/19 (37%)
Recurrent infections	15/24 (63%)	+	+	—	—	—	2/5	7/15 (47%)

+, Feature present; —, feature absent; ASD, atrial septal defect; blank, feature not reported or not verified; Cr, cryptorchidism; F, female; FOC, frontal-occipital circumference; GU, genito-urinary; Hs, hypospadias; KA, kidney anomalies; M, male; Mp, micropenis; n, number observed cases; SS, shawl scrotum; VSD, ventricular septal defect.

*Frequency of clinical manifestations among reported (n=28) OTCS patients.^{18 19 21-23}

†Only patients with pure deletion 9q34.3 summarised (n=20), including two related individuals with der(9)t(9;13)(q34.3;p12).^{1-8 10 11}

‡Frequency of feeding difficulties (gastroesophageal reflux, vomiting, aspiration).

including *MECP2* gene sequence analysis. In KCL3 and KCL4, a microdeletion of 15q12 was excluded by FISH, and a methylation assay of the *SNRPN* gene was found to be normal. Fragile X testing in patients KCL4 and KCL5 found their DNA to be normal, while the FISH result for Smith-Magenis syndrome in KCL4 was also normal.

Patient KCL1

This boy (fig 1A) presented with multiple congenital anomalies. Ultrasound showed both gonads in the inguinal canal, poor cortical medullary differentiation, and renal cysts. Both cranial CT and MRI documented the small size of the brain and hypoplasia of the inferior cerebellar vermis. Neuromotor development was significantly delayed, with poor head control. Two of the authors (FS and JGL) diagnosed the patient with an apparent OTCS-like phenotype. The respiratory difficulties triggered by viral illness worsened in the subsequent months and the child succumbed to sudden respiratory failure, refractory to treatment, at 26 months of age.

Patient KCL2

This girl (fig 1B and C) was born at 32 weeks gestation by C-section and suffered respiratory distress at birth. Patent

ductus arteriosus was confirmed echocardiographically but closed spontaneously. Neurological examination at 2 years of age exhibited normal muscle strength, but clonus and extensor plantar reflex in the lower extremities. Despite adequate movement in all extremities, she still had poor head control and was unable to roll over. She had no meaningful words. Brain MRI showed moderately enlarged cerebral ventricles and prominent frontal and temporal subarachnoid spaces bilaterally. There was significant hypomyelination of the periventricular white matter and centrum semi ovale, and a hypoplastic corpus callosum.

Patient KCL3

This girl (fig 1D) was born at full term following an uncomplicated pregnancy and normal vaginal delivery. She began rolling over at 5 months of age and neuromotor development was normal to 1 year of age. Neurological examination at 3 years of age revealed an immature pincer grasp and difficulties coordinating hand movements with preserved muscle strength and normal deep tendon reflexes. Developmentally, she was able to sit independently, pull to stand, and cruise. The gait was wide-based. There was an unusual distribution of subcutaneous fat across the shoulders. Brain MRI was abnormal only for subtle delay of

Figure 1 Facial photographs of the five subjects with 9q34.3 deletion. (A) Patient KCL1 at 1.5 years of age. (B, C) KCL2 at 3 years of age. (D) KCL3 at 4 years of age. (E, F) KCL4 at 9 years of age. (G, I) KCL5 at 4 years of age. Of note are midfacial hypoplasia, hypertelorism, broad depressed nasal bridge, small nose with upturned nares, arched eyebrows, synophrys, open "carp-like" mouth, large protruding tongue, and widely spaced teeth. (Photographs reproduced with permission)

myelination. The patient having been enrolled in a speech therapy program at 3 years of age, had learned elements of sign language by 3 years 9 months, communicated by putting two or three signs together, and recognised body parts, colours, animals, and numbers.

Patient KCL4

This girl (fig 1E and F) was born at term by induced but normal delivery after an uncomplicated pregnancy, but with concern about lack of fetal movements in the third trimester. She had no head control until 5–6 months of age and started crawling at 16 months. With her significant developmental delay, she was quite clumsy and non-verbal, but used sign language. Psychometric assessment at 4 years of age placed her at the functional level of a 26 month old child. By age 9½ years, she had developed some speech, but was still significantly delayed. Her behaviour had deteriorated and she was aggressive to family members. Picking and biting her fingernails and cuticles sometimes led to bleeding.

Patient KCL5

This boy (fig 1G and I) was born at 42 weeks gestation. Despite early intervention, his gross and fine motor development have been delayed. He began to roll over at 7 months, sat unsupported at 15 months, and walked at 2 years of age. At 3 years of age he was able to pick up small objects with a pincer-type grasp. At 4 years he was able to run, feed himself with the hands, and drink from a cup. He was unable to dress or undress himself. His speech development only consisted of a vocabulary of three words. He had no notion of either body parts or colours, and could not identify objects in picture books or videos.

Cytogenetic and FISH analyses

Cytogenetic analyses of peripheral blood were performed using standard techniques. GTG banded metaphase chromosomes were analysed at the 500–750 band resolution. The FISH assays using the commercially available 41 subtelomere specific probes were carried out on metaphase chromosomes as specified by the manufacturer (Vysis, Downers Grove, IL). A total of 18 BAC (bacterial artificial chromosomes) clones from RPCI-11 and RPCI-13 human libraries, representing a 3.4 Mb telomeric region of the long arm of chromosome 9, were selected from UCSC Genome browser ([\[genome.ucsc.edu\]\(http://genome.ucsc.edu\)\) and NCBI \(<http://www.ncbi.nlm.nih.gov>\) databases \(fig 2\). Two fosmid clones G248P80328A9 \(enclosed *ZMYND19* gene\) and G248P88772F5 \(enclosed *ARRDC1* gene\) within RP11-48C7 were selected to characterise the breakpoint of the smallest deletion. BAC and fosmid DNAs were isolated using the PSIψClone BAC DNA Kit \(Princeton Separations, Adelphia, NJ\). FISH probes were directly labelled with either Spectrum Orange-dUTP or Spectrum Green-dUTP using a commercially available kit \(Vysis\).](http://</p>
</div>
<div data-bbox=)

Bioinformatics and sequence analysis

We performed computer analysis of the DNA sequence of the most distal 3 Mb in 9q34.3 obtained from the UCSC Genome browser (<http://genome.ucsc.edu>, accessed May 2004) and, to examine for low copy repeats (LCR), compared the genome sequence against itself using the Blast 2 browser (<http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html>). The analysis for LCR has considered only the intrachromosomal segmental duplications in the chromosome 9q34.3 region.

RESULTS

Cytogenetic and FISH analyses

G banding analyses showed apparently normal karyotypes in all five patients (fig 2A–E). FISH for all chromosome specific telomeric regions revealed ish del(9)(q34.3)(D9S325-), consistent with a subtelomeric deletion of 9q in each patient, and normal hybridisation patterns for all other subtelomeres. FISH analyses with 9q region specific probes showed normal parental chromosomes in the KCL1, KCL3, KCL4, and KCL5 families. The parents of patient KCL2 were not available. Although all patients were initially reported as cytogenetically normal, a del(9)(q34.3) was suspected in two subjects (KCL1 and KCL2), parenthetically those with the largest deletions, following retrospective review of the GTG banded karyotype at the 750 band level (fig 2A and B). More detailed FISH investigations were helpful in determining the deletion sizes in each patient (fig 2F). The terminal deletions had different breakpoints in the 9q34.3 region ranging in size from ~700 kb to 2.3 Mb (table 1). Patient KCL1 was found to have the largest deletion as the proximal breakpoint mapped within two overlapping clones RP11-432J22 (not deleted) and RP11-120E1 (deleted). The deletions in patients KCL2 and KCL3 were of intermediate size. The most distal

Figure 2 Partial high resolution G banded karyotypes and ideogram of chromosome 9. (A–E) Partial karyotypes of patients KCL1, KCL2, KCL3, KCL4, and KCL5, respectively. Arrows indicate deleted chromosome 9. (F) Ideogram showing results of the deletion mapping by FISH analysis. +: Signal present on both chromosomes 9, -: signal absent on deleted chromosome 9.

breakpoint (cases KCL4 and KCL5) was found to be located between two overlapping clones RP11-48C7 (not deleted) and RP13-467E5 (deleted), hence defining the smallest deletion. We implemented fine mapping in KCL4 and KCL5 with additional fosmid clones and precisely mapped the 9q34.3 region of haploinsufficiency. The deletion is similar in size for both patients, the proximal breakpoint located between probes G248P80328A9 (not deleted) and G248P88772F5 (deleted) (fig 2F). Based on the physical distance of G248P80328A9 from the 9q telomere, we defined the smallest 9q34.3 subtelomeric deletion to a region of ~700 kb proximally flanked by the *ARRCD1* gene (fig 3).

Genotype-phenotype correlations

Detailed molecular and clinical studies were performed in our five 9q34.3 deletion patients in order to explore the genotype-phenotype correlation. Comparison of 15 subjects, consisting of ten informative patients reported in the literature and the five described herein, enabled us to construct a deletion map and to delineate 9q34.3 minimal critical regions containing potential candidate genes for the distinctive clinical features observed in monosomic patients (fig 3). We found that the association of recognisable and characteristic craniofacial features, with hypotonia, microcephaly, and global developmental delay, was present in all five of our patients and consistently found in those reported previously, regardless of deletion size. Based on the smallest deletion in our patients KCL4 and KCL5, we defined a minimal critical region of ~700 kb which is deleted in all patients (fig 3). There are at least five obese patients with del(9)(q34.3) described in the literature,^{3, 4, 8} in addition to our patients KCL4 and KCL5. The food seeking behaviour and obesity were noted in a few cases as early as 2 years of age. The frequency of obese children in this microdeletion syndrome could be underestimated due to limited clinical description or the young age of the patients. Our results suggest that the size of the 9q34.3 deletion may be important as well. Therefore, we suggest that haploinsufficiency of a gene(s) located in the minimal critical region is responsible for the common clinical findings of craniofacial dysmorphic features, hypotonia, obesity, relative microcephaly, and delay or absence of expressive speech observed in 9q34.3 monosomy.

Other manifestations such as cardiac defects, seizures, limb and brain anomalies, episodes of recurrent respiratory infections, hypothyroidism, and abnormal genitalia are detected most commonly in patients with larger deletions. For those individuals in whom an adequate clinical description was available, six critical intervals may be delineated for specific clinical manifestations (fig 3C).

Four individuals who carry a deletion over 1.6 Mb in size (case B, case C, P12, KCL1) presented with congenital anomalies including complicated CHD, anal atresia, kidney defects, abnormal pulmonary circulation, severe growth, and psychomotor retardation. Furthermore, patient KCL1, who had the largest deletion reported in the present study, exhibited trigonocephaly and a palate with a deep furrow in addition to CHD, abnormal genitalia, and capillary haemangioma, features suggestive of OTCS. While the patients over 4 years of age with small deletions showed a tendency to accelerated growth and progressive obesity, patients with the large deletion were extremely small. The various types of monosomy 9q34.3 appear to cause a recognisable complex syndrome of multiple congenital anomalies and mental retardation due to various degrees of haploinsufficiency of physically contiguous genes. Phenotypic differences between patients correlate clearly with deletion size.

DISCUSSION

In this study, we have characterised further the 9q34.3 microdeletion syndrome, a moderately distinct and recognisable clinical entity. Based on our results, we were able to delimit the ~700 kb critical region distal to the *ARRCD1* gene, as the smallest deletion associated with the del(9)(q34.3) phenotype (fig 3). Interestingly, there are only two known genes, *CACNA1B* and *EHMT1*, located in the SRO, both highly expressed in brain. The *CACNA1B* ($\alpha_{1\beta}Ca_v2.2$; MIM 601012) gene encodes the $\alpha_{1\beta}$ subunit specific for the N-type voltage dependent Ca^{2+} channels (NVDCCs). NVDCCs are predominantly localised to the nervous system and are critically involved in neurotransmitter release.^{24, 25} Selective block of the NVDCCs demonstrated their significant role in the migration of immature neurons,²⁶ whereas knockout mice deficient for $\alpha_{1\beta}Ca_v2.2$ provide evidence that the function of sympathetic neurons is predominantly regulated by NVDCCs and cannot be compensated for by other types of voltage dependent Ca^{2+} channels.²⁷ Thus, NVDCC deficiency may result in neurological dysfunction seen in the patients hemizygous for *CACNA1B*. Human microcephaly is caused by a failure of normal brain growth as a result of defects in pattern formation, cell proliferation, survival, differentiation, and/or cell growth.^{28, 29} However, observed craniofacial changes in the majority of individuals with 9q34.3 deletions cannot be easily explained by isolated haploinsufficiency of only *CACNA1B*.

EHMT1 (euchromatic histone methyltransferase; MIM 607001), a widely expressed gene, is involved in chromatin modification and is known to cause transcriptional silencing of genes. The particular role of *EHMT1* in the molecular mechanism of epigenetic transcriptional repression remains elusive. Interestingly, different authors have noted phenotypic similarity between 9q34.3 deletion subjects and patients with Prader-Willi or Rett syndrome. In particular, three patients in our study were referred for genetic testing for both syndromes. There is a possibility that *EHMT1* is involved in the same or similar biological process as *SNRPN* and *MECP2*. Remarkably, disruption of *EHMT1* was identified in a child with features of 9q deletion syndrome who carries a de novo balanced translocation t(X;9)(p11.23;q34.3).^{30, 31} These findings provide additional evidence that *EHMT1* haploinsufficiency may be responsible for the del(9)(q34.3) phenotype. At the present time, we hypothesise that both genes *CACNA1B* and *EHMT1* are dosage-sensitive and contribute to 9q34.3 deletion syndrome.

We have mapped 9q34.3 deletions in five patients and constructed a physical map of the deletions. The map encompasses 3 Mb of the distal 9q34.3 chromosomal region. Breakpoint analysis in 15 patients, for whom molecular studies were performed, did not reveal any obvious "hot-spots" for recurrent chromosome breakage in this genomic interval (fig 3). A common 400 kb breakpoint interval had been proposed previously based mostly on genotyping.¹¹ Only two of our patients have the breakpoint within the RP11-48C7 BAC clone, but seven others display a wide range of deletion sizes. For six individuals reported in the literature (P2, 5–9)¹¹ fine mapping studies were not performed. Additionally, the bioinformatic sequence analysis did not reveal intrachromosomal LCR or segmental duplications that could potentially predispose to rearrangements.

Accurate assessment of the deletion size and the definition of precise breakpoint sequences enabled us to evaluate genes within the deleted region that may contribute to the phenotype of the del(9)(q34.3) patients. Although the interpretation is limited by the number of samples studied, our analysis uncovered a correlation between the severity of the phenotype and the size of the deletion.

Figure 3 (A) Physical map of the 9q34.3 region (top) including known markers and their megabase position. The microsatellite markers are ordered approximately to scale according to their physical location in the contig. Horizontal lines show respective locations of the FISH probes (below). Filled black dots above clone 48C7 represent fosmid clones. (B) Schematic representation of the 9q34.3 deletions in 15 patients determined by FISH and genotype analyses. Five individuals (KCL1, KCL2, KCL3, KCL4, KCL5) were characterised by FISH in the present study. Clinical and molecular data on 10 informative patients reported elsewhere include patients P2, P5-9, P12,¹¹ and cases B, C, and E.⁶ The left part of the figure shows the extent of deletion in each patient. Non-deleted chromosome regions are represented by filled horizontal bars. The hatched bars identify either uninformative or inconclusive areas. The deleted regions in each patient are indicated by a double dashed line. On the right side of the figure the clinical features in the patients are given according to the initial letters of anomaly (Trigonocephaly, Genitourinary anomaly, Brain anomaly, Epilepsy or seizures, congenital Vascular and cardiac anomalies, Laxity of joints, Infection susceptibility, Craniofacial dysmorphism, Hypotonia, Obesity, Microcephaly, Speech impairment). +: feature present; -: feature absent; blank: feature not reported or not verified. (C) Phenotypic differences correlated with 9q34.3 deletion size. Open rectangles represent the proposed position of critical regions for individual clinical findings. The critical intervals defined are based on the subject with the particular phenotypic feature and the smallest deletion. Transcribed genes in the critical interval are represented by arrows; *EMHT1* is represented by a broken arrow to indicate alternative splicing.

Susceptibility to upper respiratory and ear infections, one of the frequent findings among 9q34.3 deletion patients, may be explained by aspiration due to swallowing problems and hypotonia, or to immune deficiency. Interestingly, four subjects (KCL3, KCL4, KCL5, case E) with deletions less than 1.4 Mb had persistent episodes of aspiration, but had no history of infection. In contrast to those with small deletions, patients with deletions larger than 1.4 Mb had prenatal growth retardation and frequent episodes of infection. The genes identified within this region include *TRAF2* (MIM601895), a receptor associated factor 2 of tumour necrosis factor. *Traf2*^{-/-} mice appeared normal at birth but show postnatal growth delay and die prematurely. Atrophy of the thymus and spleen also has been observed.³² Additional immunological studies are necessary to determine whether these patients truly have immune deficiency.

Another potentially interesting gene was deleted in at least two male patients with abnormal genitalia and a female patient (KCL3) with anosmia. *NELF* (MIM 608137) has been proposed as a candidate gene for the autosomal form of Kallmann syndrome (MIM 147950), with key clinical components of idiopathic hypogonadotropic hypogonadism (IHH; MIM 146110) and an- or hyposmia. Mutation of *NELF* was found in one out of 65 patients with IHH, but not in 100 normal control individuals.³³ Study of additional male individuals with deletion encompassing *NELF* is required to better characterise its haploinsufficiency.

The most severe phenotype was observed in the patients with large (>1.6 Mb) terminal deletions extending proximally beyond *NOTCH1* (MIM 190198). The patient with the largest deletion reported in our study had some OTCS manifestations. Due to phenotypic overlap, Bohring-Opitz (C-like syndrome; MIM 605039) and Baraitser-Winter (MIM 243310) syndromes were also considered and ruled out in the differential diagnosis.

The characteristic OTCS findings have not been reported in three other individuals with large deletions (fig 3), nor in patients with cytogenetically visible 9q deletions.²⁻¹⁰ As OTCS is considered to be an autosomal recessive disorder,¹⁵⁻¹⁷ the possibility exists that our patient with 9q34.3 deletion is a phenocopy or thus affected due to the unmasking of a recessive allele on the non-deleted chromosome or to the position effect of an as yet unknown gene. We hypothesise that an OTCS causative gene(s) may be located within the 9q34.3 region, and propose OTCS or OTCS-like patients should be screened for 9q34.3 microdeletions. In any event, large 9q34.3 deletions encompassing the 2.3 Mb subtelomeric region result in a very abnormal and complex phenotype with considerably reduced life expectancy. Detailed study of additional patients with the variable 9q34.3 breakpoints will likely provide further insight into the genotype-phenotype correlation and contribute to elucidation of dosage-sensitive genes.

In conclusion, our studies have reduced the size of the 9q34.3 critical region initially reported by Harada *et al*⁶ and Stewart *et al*¹¹ from ~1.0 Mb to ~700 kb distal to the *ARRDC1* gene. These deletions encompassing the *CACNA1B* and *EHMT1* genes appear to be correlated with the 9q34.3 microdeletion disorder. The extent of the deletions in the 9q34.3 contiguous gene syndrome reveals potential relevant genes for specific phenotypes. We hypothesise that alterations of a gene(s) located within 9q34.3 may be responsible for some cases of OTCS. Further studies will better clarify the function and the phenotypic consequences of haploinsufficiency for specific genes critical to the 9q34.3 deletion syndromes.

ACKNOWLEDGEMENTS

We thank the families for their cooperation in this research.

ELECTRONIC-DATABASE INFORMATION

The UCSC Genome browser database can be found at <http://genome.ucsc.edu>, the NCBI database at <http://www.ncbi.nlm.nih.gov>, and the Blast 2 browser at <http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html>.

Authors' affiliations

S A Yatsenko, S W Cheung, D A Scott, A Patel, J G Leroy, F Scaglia, P Stankiewicz, J R Lupski, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA

J R Lupski, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA

D A Scott, F Scaglia, J R Lupski, Texas Children's Hospital, Houston, TX, USA

M J M Nowaczyk, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada

M Tarnopolsky, Department of Medicine, McMaster University, Hamilton, Ontario, Canada

M Tarnopolsky, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada

S Naidu, Johns Hopkins University, Baltimore, MD, USA

S Naidu, G Bibat, Kennedy Krieger Institute, Baltimore, MD, USA

J G Leroy, Department of Medical Genetics, Ghent University Hospital, Ghent, Belgium

This study was supported in part by grants from the National Institute of Child Health and Human Development (PO1 HD39420) and the Mental Retardation Research Center (HD24064).

Competing interests: none declared

Correspondence to: Dr James R Lupski, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Room 604B, Houston, TX 77030, USA; jlupski@bcm.tmc.edu

Received 13 October 2004

Revised version received 24 November 2004

Accepted for publication 25 November 2004

REFERENCES

- 1 **Anderlid B-M**, Schoumans J, Annerén G, Sahlén S, Kyllerman M, Vujic M, Hagberg B, Blennow E, Nordenskjöld M. Subtelomeric rearrangements detected in patients with idiopathic mental retardation. *Am J Med Genet* 2002;**107**:275-84.
- 2 **Ayyash H**, Mueller R, Maltby E, Horsfield P, Telford N, Tyler R. A report of a child with a deletion 9(q34.3): a recognisable phenotype. *J Med Genet* 1997;**34**:610-2.
- 3 **Cormier-Daire V**, Molinari F, Rio M, Raoul O, de Blois M-C, Romana S, Vekemans M, Munnich A, Collea L. Cryptic terminal deletion of chromosome 9q34: a novel cause of syndromic obesity in childhood? *J Med Genet* 2003;**40**:300-3.
- 4 **Dawson AJ**, Putnam S, Schultz J, Riordan D, Prasad C, Greenberg CR, Chodirker BN, Mhanni AA, Chudley AE. Cryptic chromosome rearrangements detected by subtelomere assay in patients with mental retardation and dysmorphic features. *Clin Genet* 2002;**62**:488-94.
- 5 **Font-Montgomery E**, Weaver DD, Walsh L, Christensen C, Thurston VC. Clinical and cytogenetic manifestations of subtelomeric aberrations: report of six cases. *Birth Defects Res A Clin Mol Teratol*, 2004;**70**:408-15.
- 6 **Harada N**, Visser R, Dawson A, Fukamachi M, Iwakoshi M, Okamoto N, Kishino T, Niikawa N, Matsumoto N. A 1-Mb critical region in six patients with 9q34.3 terminal deletion syndrome. *J Hum Genet* 2004;**49**:440-4.
- 7 **Iwakoshi M**, Okamoto N, Harada N, Nakamura T, Yamamori S, Fujita H, Niikawa N, Matsumoto N. 9q34.3 deletion syndrome in three unrelated children. *Am J Med Genet* 2004;**126A**:278-83.
- 8 **Knight SJL**, Regan R, Nicod A, Horsley SW, Kearney L, Homfray T, Winter RM, Bolton P, Flint J. Subtle chromosomal rearrangements in children with unexplained mental retardation. *Lancet* 1999;**354**:1676-81.
- 9 **Quigley DI**, Kaiser-Rogers K, Aylsworth AS, Rao KW. Submicroscopic deletion 9(q34.3) and duplication 19(p13.3): identified by subtelomere specific FISH probes. *Am J Med Genet* 2004;**125A**:67-72.
- 10 **Schimenti LA**, Berry SA, Tuchman M, Hirsch B. Infant with multiple congenital anomalies and deletion 9(q34.3). *Am J Med Genet* 1994;**51**:140-2.
- 11 **Stewart DR**, Huang A, Faravelli F, Anderlid B-M, Medne L, Cipraro K, Kaur M, Rossi E, Tenconi R, Nordenskjöld M, Gripp KW, Nicholson L, Meschino WS, Capua E, Quarrelli OWJ, Flint J, Irons M, Giampietro PF, Schowalter DB, Zaleski CA, Malacarne M, Zackai EH, Spinner NB, Krantz ID. Subtelomeric

- deletions of chromosome 9q: a novel microdeletion syndrome. *Am J Med Genet* 2004;**128A**:340–51.
- 12 **Thauvin-Robinet C**, Faivre L, Cusin V, Khau Van Kien P, Callier P, Parker KL, Fellous M, Borgnon J, Gounot E, Huet F, Sapin E, Mugneret F. Cloacal exstrophy in an infant with 9q34.1-qter deletion resulting from a de novo unbalanced translocation between chromosome 9q and Yq. *Am J Med Genet* 2004;**126A**:303–7.
 - 13 **Allderice PW**, Kaita H, Lewis M, McAlpine PJ, Wong P, Anderson J, Giblett ER. Segregation of marker loci in families with an inherited paracentric insertion of chromosome 9. *Am J Hum Genet* 1986;**39**:612–7.
 - 14 **Opitz JM**, Johnson RC, McCreddie SR, Smith DW. The C syndrome of multiple congenital anomalies. *Birth Defects Orig Art Ser* 1969;**2**:161–6.
 - 15 **Antley RM**, Hwang DS, Theopold W, Gorlin RJ, Steeper T, Pitt D, Danks DM, McPherson E, Bartels H, Wiedemann H-R, Opitz JM. Further delineation of the C (trigonocephaly) syndrome. *Am J Med Genet* 1981;**9**:147–63.
 - 16 **Sargent C**, Burn J, Baraitser M, Pembrey ME. Trigonocephaly and the Opitz C syndrome. *J Med Genet* 1985;**22**:39–45.
 - 17 **Haaf T**, Hofmann R, Schmid M. Opitz trigonocephaly syndrome. *Am J Med Genet* 1991;**40**:444–6.
 - 18 **Schaap C**, Schrandt-Stumpel CTRM, Fryns JP. Opitz-C syndrome: on the nosology of mental retardation and trigonocephaly. *Genet Couns* 1992;**3**:209–15.
 - 19 **Omran H**, Hildebrandt F, Korinthenberg R, Brandis M. Probable Opitz trigonocephaly C syndrome with medulloblastoma. *Am J Med Genet* 1997;**69**:395–9.
 - 20 **McGaughan J**, Alfimos S, Oei P. Trisomy of 3pter in a patient with apparent C (trigonocephaly) syndrome. *Am J Med Genet* 2000;**94**:311–5.
 - 21 **Glickstein J**, Karasik J, Garcia Caride D, Marion RW. "C" trigonocephaly syndrome: report of a child with agenesis of the corpus callosum and tetralogy of Fallot, and review. *Am J Med Genet* 1995;**56**:215–8.
 - 22 **Zampino G**, Di Rocco C, Butera G, Balducci F, Colosimo C, Torrioli MG, Mastroiacovo P. Opitz C trigonocephaly syndrome and midline brain anomalies. *Am J Med Genet* 1997;**73**:484–8.
 - 23 **Nacarkucuk E**, Okan M, Sarimehmet H, Ozer T. Opitz trigonocephaly C syndrome associated with hearing loss. *Pediatr Int* 2003;**45**:731–3.
 - 24 **Luebke JI**, Dunlap K, Turner TJ. Multiple calcium channel types control glutamatergic synaptic transmission in the hippocampus. *Neuron* 1993;**11**:895–902.
 - 25 **Turner TJ**, Adams ME, Dunlap K. Multiple Ca^{2+} channel types coexist to regulate synaptosomal neurotransmitter release. *Proc Natl Acad Sci U S A* 1993;**90**:9518–22.
 - 26 **Burke SP**, Adams ME, Taylor CP. Inhibition of endogenous glutamate release from hippocampal tissue by Ca^{2+} channel toxins. *Eur J Pharmacol* 1993;**238**:383–6.
 - 27 **Ino M**, Yoshinaga T, Wakamori M, Miyamoto N, Takahashi E, Sonoda J, Kagaya T, Oki T, Nagasu T, Nishizawa Y, Tanaka I, Imoto K, Aizawa S, Koch S, Schwartz A, Niidome T, Sawada K, Mori Y. Functional disorders of the sympathetic nervous system in mice lacking the α_{1B} subunit ($\text{Ca}_v 2.2$) of N-type calcium channels. *Proc Natl Acad Sci U S A* 2001;**98**:5323–8.
 - 28 **Mochida GH**, Walsh CA. Molecular genetics of human microcephaly. *Curr Opin Neurol* 2001;**14**:151–6.
 - 29 **Woods CG**. Human microcephaly. *Curr Opin Neurobiol* 2004;**14**:112–7.
 - 30 **Kleefstra T**, Smidt M, Banning MJG, Oudakker AR, van Esch H, de Brouwer APM, Nillesen W, Sistermans EA, Hamel BCJ, de Bruijn D, Fryns J-P, Yntema HG, Brunner HG, de Vries BBA, van Bokhoven H. Disruption of the gene *Euchromatin Histone Methyl Transferase 1* (*Eu-HMTase1*) is associated with the 9q34 subtelomeric deletion syndrome. *J Med Genet* 2005;**42**:299–306.
 - 31 **Kleefstra T**, Yntema HG, Oudakker AR, Banning MJG, Kalscheuer VM, Chelly J, Moraine C, Ropers H-H, Fryns J-P, Janssen IM, Sistermans EA, Nillesen WN, de Vries LBA, Hamel BCJ, van Bokhoven H. Zinc finger 81 (ZNF81) mutations associated with X-linked mental retardation. *J Med Genet* 2004;**41**:394–9.
 - 32 **Yeh W-C**, Shahinian A, Speiser D, Kraunus J, Billia F, Wakeham A, de la Pompa JL, Ferrick D, Hum B, Iscove N, Ohashi P, Rothe M, Goeddel DV, Mak TW. Early lethality, functional NF- κ B activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. *Immunity* 1997;**7**:715–25.
 - 33 **Miura K**, Acierno JS Jr, Seminara SB. Characterization of the human nasal embryonic LHRH factor gene, NELF, and a mutation screening among 65 patients with idiopathic hypogonadotropic hypogonadism (IHH). *J Hum Genet* 2004;**49**:265–8.